Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

NCT06903871 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

190

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma Stage II
Esophageal Squamous Cell Carcinoma Stage III

Interventions

DRUG: TORIPALIMAB INJECTION(JS001 )

Sponsor

Hebei Medical University Fourth Hospital